Drug choices in autoimmune hepatitis: part A--Steroids.

Abstract

Prednisone and prednisolone are the mainstays of treatment for autoimmune hepatitis. Prednisone is converted in the liver to the active metabolite, prednisolone. The principal therapeutic action of prednisolone is to suppress cytokine gene expression and to inhibit the differentiation and proliferation of activated lymphocytes. It also has anti-inflammatory effects that include decreased production of adhesion molecules, increased apoptosis of lymphocytes and decreased hepatic collagen deposition. Advanced liver disease does not sufficiently suppress hepatic conversion of prednisone to warrant the preferential use of prednisolone. Budesonide combined with azathioprine has been more effective and safer than the conventional prednisone-based regimen when given for 6 months to treatment-naive patients. It is emerging as a frontline treatment, especially for noncirrhotic patients with uncomplicated disease.

• Authors: Albert J Czaja
• Journal: Expert review of gastroenterology & hepatology (Expert Rev Gastroenterol Hepatol) Vol. 6 Issue 5 Pg. 603-15 (Sep 2012) ISSN: 1747-4132 [Electronic] England
• PMID: 23061711 (Publication Type: Journal Article, Review)

Chemical References

• Glucocorticoids
• Budesonide
• Prednisolone
• Prednisone

Topics

• Budesonide (therapeutic use)
• Glucocorticoids (therapeutic use)
• Hepatitis, Autoimmune (drug therapy)
• Humans
• Prednisolone (therapeutic use)
• Prednisone (therapeutic use)